Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Niagen Bioscience's Enterprise Value for the quarter that ended in Jun. 2026 was €161.9 Mil.
Niagen Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience EV-to-EBIT Related Terms
Niagen Bioscience EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OCD1 vs CAMP, ALEC, ELDN: EV-to-EBIT Comparison
For the Packaged Foods subindustry, Niagen Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niagen Bioscience EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Niagen Bioscience's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's EV-to-EBIT falls into.
Niagen Bioscience's current Enterprise Value is €160.3 Mil.
Niagen Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience (STU:OCD1) has a EV-to-EBIT of 21.74 as of Sep. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Niagen Bioscience and its competitors. According to the industry distribution chart, Niagen Bioscience ranks #1170 out of 1568 companies in the Consumer Packaged Goods industry, placing it in the top 74.6%.
Is Niagen Bioscience's EV-to-EBIT too high?
Niagen Bioscience's current EV-to-EBIT is 21.74. The Consumer Packaged Goods industry median EV-to-EBIT is 12.51. Niagen Bioscience's value of 21.74 is 73.8% above this industry median. Based on the distribution chart, Niagen Bioscience ranks #1170 out of 1568 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Niagen Bioscience has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's EV-to-EBIT compare to CAMP and ALEC?
According to the Consumer Packaged Goods industry distribution chart, Niagen Bioscience ranks #1170 out of 1568 companies for EV-to-EBIT. This places Niagen Bioscience in the lower half of its industry. The industry median EV-to-EBIT is 12.51. Niagen Bioscience's value of 21.74 is 73.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Consumer Packaged Goods company?
The median EV-to-EBIT among Consumer Packaged Goods companies is 12.51, based on 1,568 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Niagen Bioscience's current EV-to-EBIT of 21.74 is 73.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Niagen Bioscience and its competitors. For the Consumer Packaged Goods industry, the median EV-to-EBIT is 12.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niagen Bioscience's current EV-to-EBIT is 21.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (STU:OCD1) is currently considered Possible Value Trap. The stock's GF Value™ is €4.31, compared to a current price of €2.68 — trading 37.8% below its estimated fair value. The current EV-to-EBIT is 21.74 and 73.8% above the Consumer Packaged Goods industry median of 12.51. Niagen Bioscience's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Niagen Bioscience (STU:OCD1), the current EV-to-EBIT is 21.74 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (STU:OCD1) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of €2.68 is trading 37.8% below its estimated GF Value™ of €4.31.
GuruFocus considers Niagen Bioscience to be Possible Value Trap.
Key valuation signals for STU:OCD1:
EV-to-EBIT: 21.74
GF Value™: €4.31 vs. price of €2.68 (37.8% below fair value)
Industry Position: 73.8% above the Consumer Packaged Goods median (#1170 of 1568)
No single metric tells the full story. See the STU:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
67GF Score
Get the complete analysis for STU:OCD1
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OCD1 has been successfully added to your 
